Disease progression of chronic hepatitis B and hepatitis B virus replication significantly correlated. Taiwan REVEAL study confirmed that the load of the hepatitis B virus DNA (HBVDNA) with liver cirrhosis and hepatocellular carcinoma (HCC) was positively correlated. Another study confirmed that the e antigen-positive high-risk factors for primary liver cancer. Therefore, effective suppression of hepatitis B virus replication, HBVDNA sustained suppression (real-time polymerase chain reaction (PCR) method in the detection of less than, the equivalent of 50 to 90 copies / ml) to achieve e antigen seroconversion, may slow disease progression, reduce liver sclerosis, hepatocellular carcinoma, and to extend the life of a patient, to improve the quality of life.
Antiviral therapy of chronic hepatitis B have reached a consensus. What patients need treatment? Which drug treatment? When to stop treatment? Every doctor and patient are most concerned about, the American Society for the Study of Liver Diseases (AASLD), the Asia-Pacific Liver Research Institute (APASL), the European Society of Study of the Liver (EASL) chronic hepatitis B prevention guidelines hot topic.
